Management tracks: Akouos, Kronos and Noveome

Hearing loss gene therapy play Akouos Inc. hired Rabia Gurses Ozden as chief development officer. She was CMO at Nightstar Therapeutics plc, which Biogen Inc. (NASDAQ:BIIB) acquired in June.

Kronos Bio Inc., which is developing cancer therapies against traditionally undruggable targets, expanded its management team with Christopher Lee as VP, program management, and Charles Lin as VP, biology, both newly created positions. Lee was senior director, research portfolio management at Gilead Sciences Inc. (NASDAQ:GILD), and Lin was an assistant professor of molecular and human genetics at Baylor College of Medicine...